CN112481188A - Preparation method of mixed bacterium agent for efficiently producing beta-glucuronidase - Google Patents
Preparation method of mixed bacterium agent for efficiently producing beta-glucuronidase Download PDFInfo
- Publication number
- CN112481188A CN112481188A CN202011377974.3A CN202011377974A CN112481188A CN 112481188 A CN112481188 A CN 112481188A CN 202011377974 A CN202011377974 A CN 202011377974A CN 112481188 A CN112481188 A CN 112481188A
- Authority
- CN
- China
- Prior art keywords
- escherichia coli
- mixed
- steps
- beta
- bile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000053187 Glucuronidase Human genes 0.000 title claims abstract description 17
- 108010060309 Glucuronidase Proteins 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241000894006 Bacteria Species 0.000 title claims description 25
- 241000588724 Escherichia coli Species 0.000 claims abstract description 55
- 239000007788 liquid Substances 0.000 claims abstract description 52
- 230000001580 bacterial effect Effects 0.000 claims abstract description 46
- 210000000232 gallbladder Anatomy 0.000 claims abstract description 41
- 230000000694 effects Effects 0.000 claims abstract description 33
- 210000000941 bile Anatomy 0.000 claims abstract description 29
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 241000283690 Bos taurus Species 0.000 claims abstract description 20
- 238000012216 screening Methods 0.000 claims abstract description 16
- 230000004083 survival effect Effects 0.000 claims abstract description 16
- 238000005094 computer simulation Methods 0.000 claims abstract description 10
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 9
- 230000006698 induction Effects 0.000 claims abstract description 7
- 231100000820 toxicity test Toxicity 0.000 claims abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 4
- 238000000926 separation method Methods 0.000 claims abstract description 4
- 239000006153 eosin methylene blue Substances 0.000 claims description 33
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 30
- 239000001963 growth medium Substances 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 238000012258 culturing Methods 0.000 claims description 22
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 20
- 239000004380 Cholic acid Substances 0.000 claims description 20
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 20
- 229960002471 cholic acid Drugs 0.000 claims description 20
- 235000019416 cholic acid Nutrition 0.000 claims description 20
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 20
- 229920001817 Agar Polymers 0.000 claims description 15
- 239000008272 agar Substances 0.000 claims description 15
- 239000002068 microbial inoculum Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002932 luster Substances 0.000 claims description 9
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 claims description 6
- 238000009631 Broth culture Methods 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 238000002835 absorbance Methods 0.000 claims description 6
- 239000012488 sample solution Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 claims description 6
- 230000003827 upregulation Effects 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 5
- 210000000683 abdominal cavity Anatomy 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 239000012880 LB liquid culture medium Substances 0.000 claims description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 3
- 239000003833 bile salt Substances 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 210000001096 cystic duct Anatomy 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract description 3
- 239000003613 bile acid Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 230000001850 reproductive effect Effects 0.000 abstract description 2
- 230000003592 biomimetic effect Effects 0.000 abstract 1
- 238000001952 enzyme assay Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- 206010004542 Bezoar Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/245—Escherichia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种高效产β‑葡萄糖醛酸酶混合菌剂的制备方法，包括步骤一，新鲜动物胆囊样本采集；步骤二，大肠杆菌分离；步骤三，大肠杆菌鉴定；步骤四，大肠杆菌胆汁存活筛选；步骤五，胆酸多浓度梯度定向诱导培育；步骤六，牛胆囊仿生动态模拟培育；步骤七，大肠杆菌β‑G活性测定；步骤八，菌液混合培养；步骤九，动物毒性试验检测；该发明通过胆汁和胆酸的驯化定向得到在胆汁中存活时间长、繁殖活力高的大肠杆菌菌株；通过牛胆囊仿生动态模拟得到适应胆囊环境变化的大肠杆菌菌株；通过PCR技术、菌液混合、酶活力测定得到β‑G活力高的大肠杆菌菌株；通过毒素、毒性结合筛选，得到对动物生长影响最小的大肠杆菌菌株。
The invention discloses a preparation method of a high-efficiency β-glucuronidase-producing mixed bacterial agent, including step 1, collection of fresh animal gallbladder samples; step 2, separation of Escherichia coli; Bile survival screening; step 5, multi-concentration gradient directional induction and cultivation of bile acid; step 6, biomimetic dynamic simulation cultivation of bovine gallbladder; step 7, determination of Escherichia coli β-G activity; step 8, mixed culture of bacterial liquid; step 9, animal toxicity Test and detection; the invention obtains Escherichia coli strains that survive in bile for a long time and has high reproductive activity through the domestication of bile and bile acid; Escherichia coli strains that adapt to changes in the gallbladder environment are obtained through the bionic dynamic simulation of bovine gallbladder; The Escherichia coli strain with high β-G activity was obtained by liquid mixing and enzyme activity assay; the Escherichia coli strain with the least impact on animal growth was obtained through the combination screening of toxin and toxicity.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to a preparation method of a mixed microbial inoculum for efficiently producing beta-glucuronidase.
Background
The bezoar has high medicinal value, large medical demand and very short medicine source, and the bezoar begins to be cultivated in a large area in the gall bladder of the living cow in the later period of the 20 th century and 80 th century in China, but the problems of low bezoar yield, weak medicinal effect compared with natural bezoar and the like still exist in China;
the artificially cultivated bezoar is mainly prepared by injecting sufficient Escherichia coli with beta-G activity into ox gall bladder, wherein the beta-G can hydrolyze combined Bilirubin (BDG) in ox bile to convert into free bilirubin (UCB), and the free bilirubin is one of main components forming bezoar and is a main judgment standard of medicinal value;
most studies only separate a single strain to cause yellowing, but the problems of short survival time in gall bladder, poor adaptability to gall bladder environment, low reproductive activity, low beta-glucuronidase activity and the like generally exist; aiming at the defects, a preparation method for efficiently producing the beta-glucuronidase mixed bacterial agent is necessary.
Disclosure of Invention
The invention aims to provide a preparation method of a mixed microbial inoculum for efficiently producing beta-glucuronidase, which aims to solve the problems in the background technology.
In order to solve the technical problems, the invention provides the following technical scheme: a preparation method of a mixed microbial inoculum capable of efficiently producing beta-glucuronidase comprises the steps of collecting a fresh animal gall bladder sample; step two, separating escherichia coli; step three, identifying escherichia coli; step four, survival screening of the escherichia coli bile; step five, directional induction culture of multiple concentration gradients of cholic acid; step six, bionic dynamic simulation cultivation of the cow gall bladder; seventhly, measuring the activity of the escherichia coli beta-G; step eight, mixed culture of bacterial liquid; step nine, animal toxicity test detection;
in the first step, the gall bladder of different animals such as chicken, duck, pig, cattle and the like is picked up in an artificial and sterile manner;
wherein in the second step, the separation of Escherichia coli comprises the following steps:
1) collecting bile in gallbladder with disposable syringe under aseptic condition, inoculating 0.1mL into eosin methylene blue agar culture medium EMB, simultaneously inoculating 1mL bile into 10mL, and inoculating into LB liquid culture medium for enrichment;
2) culturing in a 37 deg.C constant temperature incubator and a 37 deg.C constant temperature shaking table respectively for 16-24h, and if EMB bacteria free colony grows and LB is clear and transparent, determining that the bacteria is sterile;
3) when the EMB has no deep purple red colonies with metallic luster but the LB is turbid, 0.1mL of the LB culture medium can be taken again, and the LB culture medium is transferred to the EMB to be cultured for 16-24h at 37 ℃; if round, moist, smooth, neat-edged and medium-sized deep purple red colonies with metallic luster appear on the EMB, the numbered single suspicious colonies are picked by using a sterile inoculating loop, and the single suspicious colonies are repeatedly streaked and separated on an EMB culture medium to obtain purified colonies;
wherein in the third step, the identification of Escherichia coli comprises the following steps:
1) microscopic examination, namely aseptically picking a single purified suspicious colony, staining the single suspicious colony by using a gram stain solution, and observing the single suspicious colony under an optical microscope, wherein the colony subjected to microscopic examination is primarily judged as escherichia coli if the colony is in a red short rod shape;
2) performing PCR amplification, namely performing PCR amplification on the strains judged to be positive in the previous step, and detecting the PCR products by using 1% agarose gel electrophoresis;
wherein in the fourth step, the escherichia coli bile survival screening comprises the following steps:
1) sucking 8 mu L of the strains judged to be positive in the step three 2) by using a micropipette, and inoculating the strains into 1mL of fresh ox bile after aseptic treatment;
2) culturing at 37 deg.C for 30 days, spreading 8 μ L of the extract on eosin methylene blue agar plate, culturing at 37 deg.C, and observing whether there is colony growth, if so, determining that the strain can survive in ox bile;
in the fifth step, the directional induction culture of the cholic acid multi-concentration gradient comprises the following steps:
1) preparing 1mL of sterile broth with the cholic acid content of 12%, 15%, 18%, 21%, 24%, 27% and 30% by using No. 5 bile salt and the cholic acid content of 70% -85% and the fresh ox bile after sterile treatment;
2) selecting the bacterial colony judged to be positive in the step four 2) in 1mL of 12% cholic acid-broth culture medium by using an aseptic inoculating loop, and inoculating a loop of bacterial liquid on an eosin methylene blue agar culture medium;
3) if a green colony with metallic luster is observed, obtaining a first generation strain, then placing the first generation strain in a cholic acid-broth culture medium with the cholic acid content of 15%, repeating the steps, and acclimatizing the strain to survive and propagate in a sterile broth with the cholic acid content of more than 21%;
in the sixth step, the bionic dynamic simulation cultivation of the bovine gallbladder comprises the following steps:
1) simulating the change of the temperature of the cow gallbladder, wherein the set temperature change range is as follows: selecting the bacterial strain which is determined to be positive in the previous step by using an aseptic inoculating loop at 37 ℃, 38 ℃, 39 ℃, 40 ℃ and 41 ℃, inoculating the bacterial strain into 1mL of sterile fresh oxgall, culturing in a constant-temperature incubator at 37 ℃, adjusting the temperature up to 1 ℃ every 8h until the temperature reaches 41 ℃, taking a loop of bacterial liquid before each time of up-regulation, streaking the loop of bacterial liquid on an eosin methylene blue agar culture medium, culturing at the constant temperature of 37 ℃ for 24h, and detecting the survival activity of the bacterial strain;
2) simulating the change of bilirubin concentration of cow gallbladder TBr: preparing bilirubin solution with concentration range of 0.1755mg/mL, 0.2048mg/mL, 0.2340mg/mL, 0.2633mg/mL and 0.2925mg/mL, selecting the strains judged to be positive in the previous step by using an aseptic inoculating loop, inoculating the strains into the bilirubin-oxgall solution, and up-regulating the bilirubin concentration in the oxgall every 8 hours until the bilirubin concentration is regulated to 0.2925 mg/mL. Taking a ring of bacteria liquid before each time of up-regulation, streaking the ring of bacteria liquid on an eosin methylene blue agar culture medium, culturing at the constant temperature of 37 ℃ for 24 hours, and detecting the survival activity;
wherein in the seventh step, the activity determination of the escherichia coli beta-G comprises the following steps:
1) drawing a p-nitrophenol standard curve;
2) sample treatment: picking the best single colony grown in the last step by using a sterile inoculating loop, shaking and culturing the single colony in a 20ml LTSB culture medium for 6 hours, taking out the single colony, and adjusting the concentration of the bacterial liquid to be 1 multiplied by 108Centrifuging at 5000r/min and 4 deg.C for 10min, discarding supernatant, washing thallus with PBS for 2-3 times, centrifuging, discarding supernatant, adding 3-4mL PBS into thallus, crushing with ultrasonic cell crusher in ice bath for 30-45min at 400HZ frequency, centrifuging at 5000r/min for 10min, and collecting supernatant;
3) and (3) enzyme activity determination: sucking 80 mul of supernatant into 96 holes, adding an equivalent amount of PNPG substrate solution as a sample solution, and keeping the temperature at 36 ℃ for 1 h; sucking 80 mul, putting PBS in 96 holes, adding the same amount of PNPG substrate solution as a blank control, and keeping the temperature at 36 ℃ for 1 h; after the heat preservation of each sample is finished, taking out each hole, adding 36 mu L of NaOH solution with the concentration of 0.1mol/L to each hole to terminate the reaction, using a full-wavelength microplate reader to correct the zero point by using a blank under the wavelength of 405nm, measuring the absorbance of the sample solution, substituting the absorbance value into a standard curve equation to obtain the concentration of the p-nitrophenol, and then calculating the activity unit of the enzyme according to the following formula;
in the eighth step, the mixed culture of the bacterial liquid comprises the following steps:
1) screening out Escherichia coli combinations which are matched and mixed randomly in pairs at the concentration of 1:1 and have synergistic effect on enzyme activity, and performing concentration ratios of 1:1, 1: 2, 1: 4, 1: 8, 8: 1, 4: 1 and 2: 1 in the combinations respectively;
2) after mixed culture, measuring the enzyme activity of the mixed bacteria liquid, comparing the enzyme activity with the mixed bacteria liquid with the same combination in the concentration ratio of 1:1, and screening out the optimal pairing and concentration ratio of the mixed bacteria liquid capable of highly yielding beta-G;
wherein in the ninth step, the animal toxicity test comprises the following steps:
1) numbering the combinations of the screened mixed bacterial liquids capable of highly producing beta-G enzyme, taking 3-week-old adult mice, each group containing 6 mice, setting two groups of the mixed bacterial liquids which are respectively injected into the abdominal cavity with pathogenic escherichia coli or normal saline, and the other groups of the mixed bacterial liquids which are respectively injected into the abdominal cavity with the screened mixed bacterial liquids, each 1 × 109CFU/mL, test feeding for three weeks;
2) and (4) performing experimental feeding for three weeks, and observing whether the screened strains are non-pathogenic escherichia coli, wherein the result shows that the strains which are non-pathogenic escherichia coli are stored for later use.
According to the technical scheme, in the step one, in the collection of the fresh animal gallbladder sample, the used animal gallbladder is required to be fresh and complete, the cystic duct is ligated, and the content is not in contact with the outside.
According to the technical scheme, the shaking table in the second step 2) is 200 r/min.
According to the technical scheme, a primer is designed according to the uid and A gene which are published on Genebank and code beta-G in the step three 2).
According to the technical scheme, the step five 2) is carried out with constant temperature culture at 37 ℃ for 24 h.
According to the above technical means, in the step seven 3), β -G enzyme unit/L (U/L) is p-nitrophenol release amount (μmol)/incubation time (h)/test liquid amount (L).
Compared with the prior art, the invention has the following beneficial effects: the preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase is simple to operate, and the escherichia coli strain with long survival time and high propagation activity in bile is obtained through domestication and orientation of the bile and cholic acid; obtaining an escherichia coli strain adapting to the change of a gallbladder environment through bionic dynamic simulation of the bovine gallbladder; obtaining an escherichia coli strain with high beta-G activity by PCR technology, bacterial liquid mixing and enzyme activity determination; and through toxin and toxicity combined screening, the escherichia coli strain with the minimum influence on the growth of animals is obtained.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a flow chart of a method of the present invention;
FIG. 2 is a morphological diagram of the strain of the invention under a light microscope;
FIG. 3 is a graph of the growth of a strain of the invention;
FIG. 4 is a kinetic diagram of the beta-G activity of the strain of the invention;
FIG. 5 is a diagram showing the results of PCR identification of the gallbladder strain of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1-5, the present invention provides a technical solution: a preparation method of a mixed microbial inoculum capable of efficiently producing beta-glucuronidase comprises the steps of collecting a fresh animal gall bladder sample; step two, separating escherichia coli; step three, identifying escherichia coli; step four, survival screening of the escherichia coli bile; step five, directional induction culture of multiple concentration gradients of cholic acid; step six, bionic dynamic simulation cultivation of the cow gall bladder; seventhly, measuring the activity of the escherichia coli beta-G; step eight, mixed culture of bacterial liquid; step nine, animal toxicity test detection; the method is characterized in that:
in the first step, the gall bladder of different animals such as chickens, ducks, pigs, cows and the like is picked up manually and aseptically, and in the process of collecting a fresh animal gall bladder sample, the gall bladder of the used animal must be kept fresh and complete, the gall bladder duct is ligated, and the content is not contacted with the outside;
wherein in the second step, the separation of Escherichia coli comprises the following steps:
1) collecting bile in gallbladder with disposable syringe under aseptic condition, inoculating 0.1mL into eosin methylene blue agar culture medium EMB, simultaneously inoculating 1mL bile into 10mL, and inoculating into LB liquid culture medium for enrichment;
2) respectively culturing in a 37 deg.C constant temperature incubator and a 37 deg.C constant temperature shaking table at 200r/min for 16-24 hr, and if EMB bacteria colony grows and LB is clear and transparent, determining as bacteria free;
3) when the EMB has no deep purple red colonies with metallic luster but the LB is turbid, 0.1mL of the LB culture medium can be taken again, and the LB culture medium is transferred to the EMB to be cultured for 16-24h at 37 ℃; if round, moist, smooth, neat-edged and medium-sized deep purple red colonies with metallic luster appear on the EMB, the numbered single suspicious colonies are picked by using a sterile inoculating loop, and the single suspicious colonies are repeatedly streaked and separated on an EMB culture medium to obtain purified colonies;
wherein in the third step, the identification of Escherichia coli comprises the following steps:
1) microscopic examination, namely aseptically picking a single purified suspicious colony, staining the single suspicious colony by using a gram stain solution, and observing the single suspicious colony under an optical microscope, wherein the colony subjected to microscopic examination is primarily judged as escherichia coli if the colony is in a red short rod shape;
2) performing PCR amplification, namely performing PCR amplification on the strain judged to be positive in the previous step, designing a primer according to the uid and A genes which are disclosed on Genebank and encode beta-G, and detecting a PCR product by using 1% agarose gel electrophoresis;
wherein in the fourth step, the escherichia coli bile survival screening comprises the following steps:
1) sucking 8 mu L of the strains judged to be positive in the step three 2) by using a micropipette, and inoculating the strains into 1mL of fresh ox bile after aseptic treatment;
2) culturing at 37 deg.C for 30 days, spreading 8 μ L of the extract on eosin methylene blue agar plate, culturing at 37 deg.C, and observing whether there is colony growth, if so, determining that the strain can survive in ox bile;
in the fifth step, the directional induction culture of the cholic acid multi-concentration gradient comprises the following steps:
1) preparing 1mL of sterile broth with the cholic acid content of 12%, 15%, 18%, 21%, 24%, 27% and 30% by using No. 5 bile salt and the cholic acid content of 70% -85% and the fresh ox bile after sterile treatment;
2) selecting the bacterial colony judged to be positive in the step four 2) in 1mL of 12% cholic acid-broth culture medium by using an aseptic inoculating loop, culturing at the constant temperature of 37 ℃ for 24 hours, and inoculating a loop of bacterial liquid on an eosin methylene blue agar culture medium;
3) if a green colony with metallic luster is observed, obtaining a first generation strain, then placing the first generation strain in a cholic acid-broth culture medium with the cholic acid content of 15%, repeating the steps, and acclimatizing the strain to survive and propagate in a sterile broth with the cholic acid content of more than 21%;
in the sixth step, the bionic dynamic simulation cultivation of the bovine gallbladder comprises the following steps:
1) simulating the change of the temperature of the cow gallbladder, wherein the set temperature change range is as follows: selecting the bacterial strain which is determined to be positive in the previous step by using an aseptic inoculating loop at 37 ℃, 38 ℃, 39 ℃, 40 ℃ and 41 ℃, inoculating the bacterial strain into 1mL of sterile fresh oxgall, culturing in a constant-temperature incubator at 37 ℃, adjusting the temperature up to 1 ℃ every 8h until the temperature reaches 41 ℃, taking a loop of bacterial liquid before each time of up-regulation, streaking the loop of bacterial liquid on an eosin methylene blue agar culture medium, culturing at the constant temperature of 37 ℃ for 24h, and detecting the survival activity of the bacterial strain;
2) simulating the change of bilirubin concentration of cow gallbladder TBr: preparing bilirubin solution with concentration range of 0.1755mg/mL, 0.2048mg/mL, 0.2340mg/mL, 0.2633mg/mL and 0.2925mg/mL, selecting the strains judged to be positive in the previous step by using an aseptic inoculating loop, inoculating the strains into the bilirubin-oxgall solution, and up-regulating the bilirubin concentration in the oxgall every 8 hours until the bilirubin concentration is regulated to 0.2925 mg/mL. Taking a ring of bacteria liquid before each time of up-regulation, streaking the ring of bacteria liquid on an eosin methylene blue agar culture medium, culturing at the constant temperature of 37 ℃ for 24 hours, and detecting the survival activity;
wherein in the seventh step, the activity determination of the escherichia coli beta-G comprises the following steps:
1) drawing a p-nitrophenol standard curve;
2) sample treatment: picking the best single colony grown in the last step by using a sterile inoculating loop, shaking and culturing the single colony in a 20ml LTSB culture medium for 6 hours, taking out the single colony, and adjusting the concentration of the bacterial liquid to be 1 multiplied by 108Centrifuging at 5000r/min and 4 deg.C for 10min, discarding supernatant, washing thallus with PBS for 2-3 times, centrifuging, discarding supernatant, adding 3-4mL PBS into thallus, crushing with ultrasonic cell crusher in ice bath for 30-45min at 400HZ frequency, centrifuging at 5000r/min for 10min, and collecting supernatant;
3) and (3) enzyme activity determination: sucking 80 mul of supernatant into 96 holes, adding an equivalent amount of PNPG substrate solution as a sample solution, and keeping the temperature at 36 ℃ for 1 h; sucking 80 mul, putting PBS in 96 holes, adding the same amount of PNPG substrate solution as a blank control, and keeping the temperature at 36 ℃ for 1 h; after the heat preservation of each sample is finished, taking out each hole, adding 36 mu L of NaOH solution with the concentration of 0.1mol/L to terminate the reaction, using a full-wavelength microplate reader to correct the zero point by using a blank at the wavelength of 405nm, determining the absorbance of the sample solution, substituting the absorbance value into a standard curve equation to obtain the concentration of p-nitrophenol, and then calculating the activity unit of the enzyme according to the following formula, wherein beta-G enzyme unit/L (U/L) is p-nitrophenol release amount (mu mol)/heat preservation time (h)/liquid volume to be detected (L);
in the eighth step, the mixed culture of the bacterial liquid comprises the following steps:
1) screening out Escherichia coli combinations which are matched and mixed randomly in pairs at the concentration of 1:1 and have synergistic effect on enzyme activity, and performing concentration ratios of 1:1, 1: 2, 1: 4, 1: 8, 8: 1, 4: 1 and 2: 1 in the combinations respectively;
2) after mixed culture, measuring the enzyme activity of the mixed bacteria liquid, comparing the enzyme activity with the mixed bacteria liquid with the same combination in the concentration ratio of 1:1, and screening out the optimal pairing and concentration ratio of the mixed bacteria liquid capable of highly yielding beta-G;
wherein in the ninth step, the animal toxicity test comprises the following steps:
1) numbering the combinations of the screened mixed bacteria liquid capable of highly producing beta-G enzyme, taking 6 adult mice of 3 weeks old, setting two groups for respectively injecting pathogenic escherichia coli or physiological bacteria into abdominal cavitySaline, mixed bacterial liquid selected from the rest groups by intraperitoneal injection, each 1 × 109CFU/mL, test feeding for three weeks;
2) and (4) performing experimental feeding for three weeks, and observing whether the screened strains are non-pathogenic escherichia coli, wherein the result shows that the strains which are non-pathogenic escherichia coli are stored for later use.
The combination of E.coli strains which were mixed at a 1:1 concentration in random pairwise combinations and which were synergistic for the enzymatic activity is given in the following table:
the mixed bacterial liquid is mixed and cultured according to the concentration ratio of 1:1, 1: 2, 1: 4, 1: 8, 8: 1, 4: 1 and 2: 1, and the enzyme activity is compared with the mixed bacterial liquid with the concentration ratio of 1:1 of the same combination, and the results are shown in the table.
Based on the above, the preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase has the advantages that the operation is simple, and the escherichia coli strains with long survival time and high propagation activity in bile are directionally obtained through the domestication of the bile and the cholic acid; obtaining an escherichia coli strain adapting to the change of a gallbladder environment through bionic dynamic simulation of the bovine gallbladder; obtaining an escherichia coli strain with high beta-G activity by PCR technology, bacterial liquid mixing and enzyme activity determination; and through toxin and toxicity combined screening, the escherichia coli strain with the minimum influence on the growth of animals is obtained.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. A preparation method of a mixed microbial inoculum capable of efficiently producing beta-glucuronidase comprises the steps of collecting a fresh animal gall bladder sample; step two, separating escherichia coli; step three, identifying escherichia coli; step four, survival screening of the escherichia coli bile; step five, directional induction culture of multiple concentration gradients of cholic acid; step six, bionic dynamic simulation cultivation of the cow gall bladder; seventhly, measuring the activity of the escherichia coli beta-G; step eight, mixed culture of bacterial liquid; step nine, animal toxicity test detection; the method is characterized in that:
in the first step, the gall bladder of different animals such as chicken, duck, pig, cattle and the like is picked up in an artificial and sterile manner;
wherein in the second step, the separation of Escherichia coli comprises the following steps:
1) collecting bile in gallbladder with disposable syringe under aseptic condition, inoculating 0.1mL into eosin methylene blue agar culture medium EMB, simultaneously inoculating 1mL bile into 10mL, and inoculating into LB liquid culture medium for enrichment;
2) culturing in a 37 deg.C constant temperature incubator and a 37 deg.C constant temperature shaking table respectively for 16-24h, and if EMB bacteria free colony grows and LB is clear and transparent, determining that the bacteria is sterile;
3) when the EMB has no deep purple red colonies with metallic luster but the LB is turbid, 0.1mL of the LB culture medium can be taken again, and the LB culture medium is transferred to the EMB to be cultured for 16-24h at 37 ℃; if round, moist, smooth, neat-edged and medium-sized deep purple red colonies with metallic luster appear on the EMB, the numbered single suspicious colonies are picked by using a sterile inoculating loop, and the single suspicious colonies are repeatedly streaked and separated on an EMB culture medium to obtain purified colonies;
wherein in the third step, the identification of Escherichia coli comprises the following steps:
1) microscopic examination, namely aseptically picking a single purified suspicious colony, staining the single suspicious colony by using a gram stain solution, and observing the single suspicious colony under an optical microscope, wherein the colony subjected to microscopic examination is primarily judged as escherichia coli if the colony is in a red short rod shape;
2) performing PCR amplification, namely performing PCR amplification on the strains judged to be positive in the previous step, and detecting the PCR products by using 1% agarose gel electrophoresis;
wherein in the fourth step, the escherichia coli bile survival screening comprises the following steps:
1) sucking 8 mu L of the strains judged to be positive in the step three 2) by using a micropipette, and inoculating the strains into 1mL of fresh ox bile after aseptic treatment;
2) culturing at 37 deg.C for 30 days, spreading 8 μ L of the extract on eosin methylene blue agar plate, culturing at 37 deg.C, and observing whether there is colony growth, if so, determining that the strain can survive in ox bile;
in the fifth step, the directional induction culture of the cholic acid multi-concentration gradient comprises the following steps:
1) preparing 1mL of sterile broth with the cholic acid content of 12%, 15%, 18%, 21%, 24%, 27% and 30% by using No. 5 bile salt and the cholic acid content of 70% -85% and the fresh ox bile after sterile treatment;
2) selecting the bacterial colony judged to be positive in the step four 2) in 1mL of 12% cholic acid-broth culture medium by using an aseptic inoculating loop, and inoculating a loop of bacterial liquid on an eosin methylene blue agar culture medium;
3) if a green colony with metallic luster is observed, obtaining a first generation strain, then placing the first generation strain in a cholic acid-broth culture medium with the cholic acid content of 15%, repeating the steps, and acclimatizing the strain to survive and propagate in a sterile broth with the cholic acid content of more than 21%;
in the sixth step, the bionic dynamic simulation cultivation of the bovine gallbladder comprises the following steps:
1) simulating the change of the temperature of the cow gallbladder, wherein the set temperature change range is as follows: selecting the bacterial strain which is determined to be positive in the previous step by using an aseptic inoculating loop at 37 ℃, 38 ℃, 39 ℃, 40 ℃ and 41 ℃, inoculating the bacterial strain into 1mL of sterile fresh oxgall, culturing in a constant-temperature incubator at 37 ℃, adjusting the temperature up to 1 ℃ every 8h until the temperature reaches 41 ℃, taking a loop of bacterial liquid before each time of up-regulation, streaking the loop of bacterial liquid on an eosin methylene blue agar culture medium, culturing at the constant temperature of 37 ℃ for 24h, and detecting the survival activity of the bacterial strain;
2) simulating the change of bilirubin concentration of cow gallbladder TBr: preparing bilirubin solution with concentration range of 0.1755mg/mL, 0.2048mg/mL, 0.2340mg/mL, 0.2633mg/mL and 0.2925mg/mL, selecting the strains judged to be positive in the previous step by using an aseptic inoculating loop, inoculating the strains into the bilirubin-oxgall solution, and up-regulating the bilirubin concentration in the oxgall every 8 hours until the bilirubin concentration is regulated to 0.2925 mg/mL. Taking a ring of bacteria liquid before each time of up-regulation, streaking the ring of bacteria liquid on an eosin methylene blue agar culture medium, culturing at the constant temperature of 37 ℃ for 24 hours, and detecting the survival activity;
wherein in the seventh step, the activity determination of the escherichia coli beta-G comprises the following steps:
1) drawing a p-nitrophenol standard curve;
2) sample treatment: picking the best single colony grown in the last step by using a sterile inoculating loop, shaking and culturing the single colony in a 20ml LTSB culture medium for 6 hours, taking out the single colony, and adjusting the concentration of the bacterial liquid to be 1 multiplied by 108Centrifuging at 5000r/min and 4 deg.C for 10min, discarding supernatant, washing thallus with PBS for 2-3 times, centrifuging, discarding supernatant, adding 3-4mL PBS into thallus, crushing with ultrasonic cell crusher in ice bath for 30-45min at 400HZ frequency, centrifuging at 5000r/min for 10min, and collecting supernatant;
3) and (3) enzyme activity determination: sucking 80 mul of supernatant into 96 holes, adding an equivalent amount of PNPG substrate solution as a sample solution, and keeping the temperature at 36 ℃ for 1 h; sucking 80 mul, putting PBS in 96 holes, adding the same amount of PNPG substrate solution as a blank control, and keeping the temperature at 36 ℃ for 1 h; after the heat preservation of each sample is finished, taking out each hole, adding 36 mu L of NaOH solution with the concentration of 0.1mol/L to each hole to terminate the reaction, using a full-wavelength microplate reader to correct the zero point by using a blank under the wavelength of 405nm, measuring the absorbance of the sample solution, substituting the absorbance value into a standard curve equation to obtain the concentration of the p-nitrophenol, and then calculating the activity unit of the enzyme according to the following formula; in the eighth step, the mixed culture of the bacterial liquid comprises the following steps:
1) screening out Escherichia coli combinations which are matched and mixed randomly in pairs at the concentration of 1:1 and have synergistic effect on enzyme activity, and performing concentration ratios of 1:1, 1: 2, 1: 4, 1: 8, 8: 1, 4: 1 and 2: 1 in the combinations respectively;
2) after mixed culture, measuring the enzyme activity of the mixed bacteria liquid, comparing the enzyme activity with the mixed bacteria liquid with the same combination in the concentration ratio of 1:1, and screening out the optimal pairing and concentration ratio of the mixed bacteria liquid capable of highly yielding beta-G;
wherein in the ninth step, the animal toxicity test comprises the following steps:
1) numbering the combinations of the screened mixed bacterial liquids capable of highly producing beta-G enzyme, taking 3-week-old adult mice, each group containing 6 mice, setting two groups of the mixed bacterial liquids which are respectively injected into the abdominal cavity with pathogenic escherichia coli or normal saline, and the other groups of the mixed bacterial liquids which are respectively injected into the abdominal cavity with the screened mixed bacterial liquids, each 1 × 109CFU/mL, test feeding for three weeks;
2) and (4) performing experimental feeding for three weeks, and observing whether the screened strains are non-pathogenic escherichia coli, wherein the result shows that the strains which are non-pathogenic escherichia coli are stored for later use.
2. The preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase according to claim 1, which is characterized by comprising the following steps: in the step one, during the collection of a fresh animal gallbladder sample, the used animal gallbladder must be kept fresh and complete, the cystic duct is ligated and the content is not in contact with the outside.
3. The preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase according to claim 1, which is characterized by comprising the following steps: the shaking table in the second step 2) is 200 r/min.
4. The preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase according to claim 1, which is characterized by comprising the following steps: in the step three 2), a primer is required to be designed according to the uid and A gene which are published on Genebank and code beta-G.
5. The preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase according to claim 1, which is characterized by comprising the following steps: the step five 2) is cultured for 24 hours at the constant temperature of 37 ℃.
6. The preparation method of the mixed microbial inoculum for efficiently producing the beta-glucuronidase according to claim 1, which is characterized by comprising the following steps: and (c) in the step seven 3), wherein the beta-G enzyme unit/L (U/L) is p-nitrophenol release amount (mu mol)/incubation time (h)/liquid volume to be detected (L).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011377974.3A CN112481188A (en) | 2020-11-30 | 2020-11-30 | Preparation method of mixed bacterium agent for efficiently producing beta-glucuronidase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011377974.3A CN112481188A (en) | 2020-11-30 | 2020-11-30 | Preparation method of mixed bacterium agent for efficiently producing beta-glucuronidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112481188A true CN112481188A (en) | 2021-03-12 |
Family
ID=74937757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011377974.3A Pending CN112481188A (en) | 2020-11-30 | 2020-11-30 | Preparation method of mixed bacterium agent for efficiently producing beta-glucuronidase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112481188A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116004575A (en) * | 2022-07-29 | 2023-04-25 | 济南大学 | Beta-glucuronidase and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1563393A (en) * | 2004-04-06 | 2005-01-12 | 周广礼 | Method for preparing natural bezoar promoted by enzyme |
| CN101474209A (en) * | 2009-01-23 | 2009-07-08 | 刘化侠 | Preparation method of enzyme induced bezoar |
| CN102512457A (en) * | 2011-12-21 | 2012-06-27 | 武汉健民大鹏药业有限公司 | Method for preparing composite calcium bilirubinate from ox gall |
| CN107177523A (en) * | 2017-03-22 | 2017-09-19 | 四川农业大学 | The cultural method of the Escherichia coli of One serotype |
| CN111939177A (en) * | 2019-04-30 | 2020-11-17 | 千芝堂生命科学(深圳)有限公司 | Combined medicine for being implanted into gallbladder, gallbladder implant containing combined medicine and application of gallbladder implant in-vivo cultivation of bezoar |
-
2020
- 2020-11-30 CN CN202011377974.3A patent/CN112481188A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1563393A (en) * | 2004-04-06 | 2005-01-12 | 周广礼 | Method for preparing natural bezoar promoted by enzyme |
| CN101474209A (en) * | 2009-01-23 | 2009-07-08 | 刘化侠 | Preparation method of enzyme induced bezoar |
| CN102512457A (en) * | 2011-12-21 | 2012-06-27 | 武汉健民大鹏药业有限公司 | Method for preparing composite calcium bilirubinate from ox gall |
| CN107177523A (en) * | 2017-03-22 | 2017-09-19 | 四川农业大学 | The cultural method of the Escherichia coli of One serotype |
| CN111939177A (en) * | 2019-04-30 | 2020-11-17 | 千芝堂生命科学(深圳)有限公司 | Combined medicine for being implanted into gallbladder, gallbladder implant containing combined medicine and application of gallbladder implant in-vivo cultivation of bezoar |
Non-Patent Citations (5)
| Title |
|---|
| KER C-G等: ""A STUDY OF THE RELATIONSHIP BETWEEN BETA GLUCURONIDASE AND CHOLELITHIASIS II. ACTIVITY OF ESCHERICHIA-COLI AND THEIR OK ANTIGEN SEROTYPES"", 《KAOHSIUNG JOURNAL OF MEDICAL SCIENCES》 * |
| 修金生，林立中: ""牛黄菌种的选育、驯化与鉴定"", 《福建畜牧兽医》 * |
| 修金生等: ""不同大肠杆菌菌株的β－葡萄糖醛酸酶活性及对培植牛黄产量与胆红素含量的影响"", 《福建农业大学学报》 * |
| 周广礼等: ""以大肠杆菌β-葡萄糖醛酸酶培育牛黄实验研究"", 《泰山医学院学报》 * |
| 杨光: ""β-G酶活性不同的大肠杆菌对体外培植牛黄产量与质量的影响"", 《中国优秀硕士学位论文全文数据库（电子期刊）-农业科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116004575A (en) * | 2022-07-29 | 2023-04-25 | 济南大学 | Beta-glucuronidase and application thereof |
| CN116004575B (en) * | 2022-07-29 | 2024-03-15 | 济南大学 | A kind of beta-glucuronidase and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109182184B (en) | A canine Pediococcus lactis strain and its application | |
| CN105816868B (en) | Inactivated vaccine for mycoplasma synoviae | |
| CN107338198A (en) | A kind of Lactobacillus plantarum and its application | |
| CN111304119B (en) | Feeding bacillus subtilis for degrading fumonisins and application thereof | |
| CN112029696B (en) | Edwardsiella piscicola derived from turbot and application thereof | |
| CN104498441A (en) | Duck hepatitis A virus III type attenuated strain, live vaccine prepared from same and application of live vaccine | |
| CN112574924A (en) | Bacillus subtilis strain, microecological preparation and application thereof | |
| CN117965358A (en) | Bile-tolerant xanthogen and application thereof | |
| CN112239736B (en) | Bacillus amyloliquefaciens, microbial inoculum, screening method and application | |
| CN116240123A (en) | A strain of Paenibacillus polymyxa, its microecological preparation and its preparation method | |
| CN115710566B (en) | Strain for comprehensive planting and breeding of rice field and application thereof | |
| CN104258386B (en) | A kind of mink viral enteritis inactivated vaccine-canine distemper live vaccine combination | |
| CN106387314A (en) | Applications of Bacteroides fragilis in animal breeding | |
| CN108949619A (en) | A kind of zymotechnique of riemerella anatipestifer | |
| CN105274064B (en) | A kind of duck tembusu virus attenuated vaccine strain and its application | |
| CN112481188A (en) | Preparation method of mixed bacterium agent for efficiently producing beta-glucuronidase | |
| CN109486714A (en) | A kind of weak malicious separation strains of avian infectious bronchitis nephritis virus and its application | |
| CN117844686A (en) | Separation, identification and application of avibacterium paragallinarum serum A strain with cross protection effect | |
| CN113755368B (en) | A Fujian Chicken Mycoplasma Synovium and Its Culture Medium | |
| RU2518304C2 (en) | TWO-PHASE NUTRITIONAL MEDIUM FOR THIN LAYER CULTIVATION OF Helicobacter pylori AND METHOD OF ITS REALISATION | |
| CN105169380A (en) | Bivalent propolis inactivated vaccine for rabbit hemorrhagic disease and multocida pasteurellosis and preparation method of bivalent propolis inactivated vaccine | |
| Khan et al. | Biomass production of Pasteurella multocida using biofermenter | |
| CN109010814A (en) | The production method of haemophilus parasuis and mycoplasma hyopneumoniae bivalent inactivated vaccine | |
| CN105749266B (en) | Mink hemorrhagic pneumonia and clostridium botulinum poisoning bivalent inactivated vaccine and preparation method thereof | |
| CN115261287A (en) | Composite lactobacillus microbial inoculum and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210312 |